August 3, 2017 10:41 AM EDT

Teva talks tough on cuts; Takeda bolsters startup with a dedicated cardio discovery team

Shehla Shakoor

Managing Director

→ With its share price plummeting as the revenue numbers deteriorate at a rapid pace, Israel’s troubled Teva talked up deep cuts today, with plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teva talks tough on cuts; Takeda bolsters startup with a dedicated cardio discovery team

Shehla Shakoor

Managing Director

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Te­va talks tough on cuts; Take­da bol­sters start­up with a ded­i­cat­ed car­dio dis­cov­ery team

Managing Director

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Teva talks tough on cuts; Takeda bolsters startup with a dedicated cardio discovery team